Tucaresol

Tucaresol

SCHEMBL600942

O=Cc1c(O)cccc1OCc1ccc(C(=O)O)cc1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 9/20 0.56
RXRB P28702 8/20 0.56
RXRG P48443 7/20 0.56
HPGD P15428 3/20 0.56
FOLH1 Q04609 1/20 0.54
PTGER1 P34995 1/20 0.50
PTGER4 P35408 1/20 0.50
PTGER3 P43115 1/20 0.50
PTGER2 P43116 1/20 0.50
KDM4E B2RXH2 1/20 0.49
PSMD14 O00487 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
CRHBP P24387 1/20 0.49
PPARG P37231 1/20 0.49
KMT2A Q03164 1/20 0.49
CRHR2 Q13324 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
NR4A2 P43354 2/20 0.48
NR4A1 P22736 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tucaresol SCHEMBL29400654 1.00 RXRA (0.56) RXRARXRBRXRGHPGDFOLH1
SCHEMBL23383954 0.88 MAOB (0.53) RXRARXRBRXRGALDH1A1MAPT
SCHEMBL2370214 0.87 MAPT (0.57) FOLH1PTGER1PTGER4PTGER3PTGER2
SCHEMBL6027574 0.86 MRGPRX4 (0.60) RXRARXRBHPGDFOLH1KMT2A
SCHEMBL27565831 0.85 PTGER1 (0.47) RXRARXRBRXRGHPGDFOLH1
SCHEMBL24702757 0.85 RAB9A (0.49) RXRARXRBRXRGHPGDFOLH1
SCHEMBL5756261 0.85 MAPT (0.61) RXRAHPGDKDM4EALDH1A1MAPT
SCHEMBL23383726 0.85 POLB (0.54) RXRARXRBRXRGHPGDFOLH1
SCHEMBL23383976 0.85 RXRA (0.70) RXRARXRBRXRGHPGDFOLH1
SCHEMBL21798467 0.85 RXRA (0.70) RXRARXRBRXRGHPGDFOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230255963-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION GLOBAL BLOOD THERAPEUTICS INC (US) 2023-08-17 US claimed
US-20220125786-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION GLOBAL BLOOD THERAPEUTICS INC (US) 2022-04-28 US claimed
US-20210290619-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION GLOBAL BLOOD THERAPEUTICS, INC. 2021-09-23 US claimed
US-20180369281-A1 METHOD OF AMELIORATING SIDE EFFECTS OF SICKLE CELL DISEASE TREATMENTS ALBERT EINSTEIN COLLGE OF MEDICINE, INC. (US) 2018-12-27 US claimed
WO-2017083281-A1 METHOD OF AMELIORATING SIDE EFFECTS OF SICKLE CELL DISEASE TREATMENTS ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) 2017-05-18 WO claimed
US-20150344472-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION GLOBAL BLOOD THERAPEUTICS, INC. 2015-12-03 US claimed
EP-2797416-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION Global Blood Therapeutics, Inc. (US) 2014-11-05 EP claimed
US-20130190315-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION GLOBAL BLOOD THERAPEUTICS, INC. (US) 2013-07-25 US claimed
WO-2013102142-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION GLOBAL BLOOD THERAPEUTICS, INC. (US) 2013-07-04 WO claimed
EP-1107785-B1 METHOD OF DNA VACCINATION GLAXO GROUP LTD (GB) 2008-10-15 EP claimed
US-5872151-A ADMINISTERING TO AN IMMUNODEFICIENT PATIENT FOR TREATMENT OF VIRUS INFECTIONS AN IMMUNOPOTENTIATORY AMOUNT OF 4-(2-FORMYL-3-HYDROXYPHENOXYMETHYL)BENZOIC ACID OR SALTS GLAXO WELLCOME INC. (US) 1999-02-16 US claimed
EP-0609606-B1 Tucaresol as an immunopotentiatory agent WELLCOME FOUND (GB) 1996-12-11 EP claimed
US-5508310-A ADMINISTERING SUBSTITUTED ALDEHYDES OR KETONES WHICH CAN REACT WITH T-CELL SURFACE GROUPS TO FORM SCHIFF BASES BURROUGHS WELLCOME CO. (US) 1996-04-16 US claimed
EP-0678298-A2 Use of 4-(2-formyl-3-hydroxyphenoxymethyl)benzoic acid as immopotentiatory agent THE WELLCOME FOUNDATION LIMITED (GB) 1995-10-25 EP claimed
EP-0614357-A1 IMMUNOPOTENTIATORY AGENTS THE WELLCOME FOUNDATION LIMITED (GB) 1994-09-14 EP claimed
EP-0609606-A1 Tucaresol as an immunopotentiatory agent THE WELLCOME FOUNDATION LIMITED (GB) 1994-08-10 EP claimed
WO-1994007479-A2 IMMUNOPOTENTIATORY AGENTS THE WELLCOME FOUNDATION LIMITED (GB) 1994-04-14 WO claimed
EP-0054924-B1 PHARMACEUTICAL COMPOUNDS, THEIR PREPARATION AND USE THE WELLCOME FOUNDATION LIMITED (GB) 1986-08-06 EP claimed
US-4535183-A PALLIATION OF SICKLE CELL ANEMIA, RESPIRATORY DISORDERS, HYPOXIA, RADIOSENSITIZATION OF TUMORS BURROUGHS WELLCOME CO. (US) 1985-08-13 US claimed
EP-0054924-A2 Pharmaceutical compounds, their preparation and use THE WELLCOME FOUNDATION LIMITED (GB) 1982-06-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344472-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION HBB, HBG2, MB RXRA 2016/4885RXRB 1425/4885RXRG 1766/4885
US-20230255963-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION HBB, HBG2, MB RXRA 2016/4885RXRB 1425/4885RXRG 1766/4885
US-20220125786-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION HBB, HBG2, MB RXRA 2016/4885RXRB 1425/4885RXRG 1766/4885
US-20130190315-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION HBB, HBG2, MB RXRA 2016/4885RXRB 1425/4885RXRG 1766/4885
US-20180369281-A1 METHOD OF AMELIORATING SIDE EFFECTS OF SICKLE CELL DISEASE TREATMENTS HBG1, HBG2, HBB RXRA 2317/4885RXRB 1942/4885RXRG 1979/4885
US-20210290619-A1 SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION HBB, HBG2, MB RXRA 2016/4885RXRB 1425/4885RXRG 1766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.